B Flechl1, C Sax2, M Ackerl2, R Crevenna3, A Woehrer4, J Hainfellner4, M Preusser2, G Widhalm5, B Kiesel5, C Lütgendorf-Caucig6, K Dieckmann6, C Steffal7, C Marosi8, M R Hassler9. 1. Department of Medicine I, Medical University of Vienna, Comprehensive Cancer Center-Central Nervous System Tumors Unit (CCC-CNS), Vienna, Austria; Institute of Radiation Oncology, Kaiser-Franz-Josef Hospital, Vienna, Austria; MedAustron Ion Therapy Center, Wiener Neustadt, Austria. 2. MedAustron Ion Therapy Center, Wiener Neustadt, Austria. 3. Department of Physical Medicine and Rehabilitation, Medical University of Vienna, Austria. 4. Institute of Neurology, Medical University of Vienna, Austria. 5. Department of Neurosurgery, Medical University of Vienna, Austria. 6. Department of Radiation Oncology, Medical University of Vienna, Austria. 7. Department of Medicine I, Medical University of Vienna, Comprehensive Cancer Center-Central Nervous System Tumors Unit (CCC-CNS), Vienna, Austria. 8. MedAustron Ion Therapy Center, Wiener Neustadt, Austria. Electronic address: christine.marosi@meduniwien.ac.at. 9. Department of Medicine I, Medical University of Vienna, Comprehensive Cancer Center-Central Nervous System Tumors Unit (CCC-CNS), Vienna, Austria; Sonnberghof, Bad Sauerbrunn, Austria.
Abstract
BACKGROUND: The importance of QoL and neurocognitive functions in patients with glioblastoma (GB) is above controversy by now. We followed newly diagnosed GB patients treated with radio-chemotherapy during their course of disease by continuously evaluating their quality of life (QoL) and cognitive functions. METHODS: We included consecutive patients with newly diagnosed GB from 2010 to 2013 at the Medical University of Vienna. To assess QoL the EORTC QLQ C30 and BN20 questionnaire were used. Neurocognition was measured with the NeuroCog FX. The evaluations were done 6 times every three months, beginning at the beginning of radio-chemotherapy. RESULTS: 42 patients participated in this study. We also recorded QoL and neurocognition in 23 patients after the first disease progression. Patients maintained their cognitive summary score until relapse. Patients with left-sided tumors showed significant lower scores in the subscale verbal fluency than patients with right-sided tumors. The global health score of QoL decreased after the fifth evaluation (13months after diagnosis) whereas a peak of fatigue symptoms was obtained at the third evaluation. Furthermore, fatigue symptoms increased strongly 7months after diagnosis and patients' financial difficulties were mentioned more frequently by younger patients and in patients with lower education levels. CONCLUSIONS: QoL and cognitive long-term assessments are feasible also in some patients with GB after a symptomatic progression. Our study demonstrates maintenance of QoL and cognitive summary scales before tumor progression. Moreover, it highlights subgroups according to tumor location and socioeconomic factors.
BACKGROUND: The importance of QoL and neurocognitive functions in patients with glioblastoma (GB) is above controversy by now. We followed newly diagnosed GB patients treated with radio-chemotherapy during their course of disease by continuously evaluating their quality of life (QoL) and cognitive functions. METHODS: We included consecutive patients with newly diagnosed GB from 2010 to 2013 at the Medical University of Vienna. To assess QoL the EORTC QLQ C30 and BN20 questionnaire were used. Neurocognition was measured with the NeuroCog FX. The evaluations were done 6 times every three months, beginning at the beginning of radio-chemotherapy. RESULTS: 42 patients participated in this study. We also recorded QoL and neurocognition in 23 patients after the first disease progression. Patients maintained their cognitive summary score until relapse. Patients with left-sided tumors showed significant lower scores in the subscale verbal fluency than patients with right-sided tumors. The global health score of QoL decreased after the fifth evaluation (13months after diagnosis) whereas a peak of fatigue symptoms was obtained at the third evaluation. Furthermore, fatigue symptoms increased strongly 7months after diagnosis and patients' financial difficulties were mentioned more frequently by younger patients and in patients with lower education levels. CONCLUSIONS: QoL and cognitive long-term assessments are feasible also in some patients with GB after a symptomatic progression. Our study demonstrates maintenance of QoL and cognitive summary scales before tumor progression. Moreover, it highlights subgroups according to tumor location and socioeconomic factors.
Authors: Chengcheng Gui; Tracy D Vannorsdall; Lawrence R Kleinberg; Ryan Assadi; Joseph A Moore; Chen Hu; Alfredo Quiñones-Hinojosa; Kristin J Redmond Journal: Neurosurgery Date: 2020-07-01 Impact factor: 4.654
Authors: Paul D Brown; Caroline Chung; Diane D Liu; Sarah McAvoy; David Grosshans; Karine Al Feghali; Anita Mahajan; Jing Li; Susan L McGovern; Mary-Fran McAleer; Amol J Ghia; Erik P Sulman; Marta Penas-Prado; John F de Groot; Amy B Heimberger; Jihong Wang; Terri S Armstrong; Mark R Gilbert; Nandita Guha-Thakurta; Jeffrey S Wefel Journal: Neuro Oncol Date: 2021-08-02 Impact factor: 12.300
Authors: Sophie J M Rijnen; Elke Butterbrod; Geert-Jan M Rutten; Margriet M Sitskoorn; Karin Gehring Journal: Neurosurgery Date: 2020-11-16 Impact factor: 4.654
Authors: Joshua D Palmer; Gordon Chavez; Wesley Furnback; Po-Ya Chuang; Bruce Wang; Christina Proescholdt; Chao-Hsiun Tang Journal: Front Oncol Date: 2021-12-02 Impact factor: 6.244
Authors: Tomas Kazda; Adam Dziacky; Petr Burkon; Petr Pospisil; Marek Slavik; Zdenek Rehak; Radim Jancalek; Pavel Slampa; Ondrej Slaby; Radek Lakomy Journal: Radiol Oncol Date: 2018-06-06 Impact factor: 4.214